Klotho Neurosciences, Inc. (NASDAQ:KLTO) Sees Significant Decrease in Short Interest

Klotho Neurosciences, Inc. (NASDAQ:KLTO) was the recipient of a significant decline in short interest in January. As of January 15th, there was short interest totaling 391,815 shares, a decline of 18.8% from the December 31st total of 482,725 shares. Based on an average trading volume of 648,138 shares, the days-to-cover ratio is presently 0.6 days. Approximately 0.7% of the shares of the stock are short sold. Approximately 0.7% of the shares of the stock are short sold. Based on an average trading volume of 648,138 shares, the days-to-cover ratio is presently 0.6 days.

Hedge Funds Weigh In On Klotho Neurosciences

A hedge fund recently bought a new stake in Klotho Neurosciences stock. Jane Street Group LLC bought a new stake in shares of Klotho Neurosciences, Inc. (NASDAQ:KLTO) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund bought 23,364 shares of the company’s stock, valued at approximately $26,000. Jane Street Group LLC owned 0.05% of Klotho Neurosciences as of its most recent SEC filing. Hedge funds and other institutional investors own 20.07% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Klotho Neurosciences in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Klotho Neurosciences Stock Down 0.8%

Shares of NASDAQ KLTO traded down $0.00 during mid-day trading on Monday, hitting $0.27. 654,789 shares of the company traded hands, compared to its average volume of 592,751. Klotho Neurosciences has a 1 year low of $0.11 and a 1 year high of $3.91. The stock has a market capitalization of $19.78 million, a price-to-earnings ratio of -0.84 and a beta of 10.27. The business has a 50 day moving average of $0.36 and a two-hundred day moving average of $0.56.

Klotho Neurosciences (NASDAQ:KLTO) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.05) earnings per share (EPS) for the quarter.

About Klotho Neurosciences

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.